SAB Biotherapeutics, Inc. develops fully human anti-thymocyte immunoglobulin and multi-specific human immunoglobulin G therapies for type 1 diabetes and other autoimmune diseases. Its lead program, SAB-142, is a disease-focused immunotherapy candidate for autoimmune type 1 diabetes, supported by the company’s transchromosomic cattle, or Tc-Bovine, production system for generating targeted hIgG antibodies.
Recurring news themes include SAB-142 clinical and mechanistic data, scientific conference presentations, financial results and business updates, and capital actions such as common stock and pre-funded warrant offerings that fund clinical development, manufacturing, regulatory activity and general corporate purposes.
SAB Biotherapeutics (SABS) announced that its management team will participate in four investor conferences during November and December 2026. CEO Samuel J. Reich will give fireside chats at Jefferies on November 16 and UBS on November 17, both in London, and Evercore on December 1 in Coral Gables, Florida. Management will hold one-on-one meetings at Citi’s conference on December 2 in Miami.
SAB BIO (Nasdaq: SABS) reported a third-quarter 2026 net loss of $22.3 million while advancing SAB-142 clinical studies in type 1 diabetes. The company reported net income of $45.4 million a year earlier. Research and development expenses rose to $18.1 million from $9.0 million, while general and administrative expenses increased to $7.8 million from $3.7 million.
Cash, cash equivalents and investment securities totaled $205.3 million at September 30; SAB BIO expects operational runway through 2028. Adult and adolescent enrollment in the registrational Phase 2b SAFEGUARD study is complete, with children ages 5–11 enrolling. The company targets full enrollment in Q4 2026 and topline data in the second half of 2027. SAB-142 received FDA Fast Track designation in October for new-onset Stage 3 type 1 diabetes. The Phase 3 PRISE-hATG study expects to dose its first patient in Q4 2026.
SAB Biotherapeutics (Nasdaq: SABS) will release its third-quarter 2026 financial results on the morning of November 5, 2026. Management will host a conference call and webcast at 08:30 AM ET that day to discuss the results and provide business updates. An audio webcast replay will be available afterward in the Investors & Media section of the company’s website.
SAB BIO (Nasdaq: SABS) will participate in the Chardan 10th Annual Healthcare Conference on October 20, 2026, in New York.
Chief Executive Officer Samuel J. Reich will present in a fireside chat from 11:15 to 11:30 a.m. ET. Management will also be available for one-on-one meetings, which interested parties can arrange through their conference representative.
SAB BIO (SABS) received FDA Fast Track designation for SAB-142, an immunotherapy being developed for people with new-onset Stage 3 type 1 diabetes.
Fast Track is intended to facilitate development and expedite review of therapies for serious conditions with an unmet medical need. SAB-142 is a potentially disease-modifying, fully human anti-thymocyte immunoglobulin, a type of immune therapy. It is currently being evaluated in the registrational Phase 2b SAFEGUARD study in people within 100 days of a Stage 3 diagnosis. SAB BIO expects enrollment to be completed in Q4 2026 and anticipates topline data in 2H 2027.
The program is also supported by the investigator-led Phase 3 PRISE-hATG study, designed to evaluate SAB-142 in people from 100 days to two years after a Stage 3 type 1 diabetes diagnosis.
SAB BIO (SABS) will present encore Phase 1 SAB-142 data at the Breakthrough T1D Clinical & Research Congress on October 9–11, 2026.
The Philadelphia conference presentations will address the investigational Stage 3 type 1 diabetes immunotherapy’s mechanism of action, potential for repeat dosing and early C-peptide response, a measure related to insulin production. SAB BIO said presentations will feature available safety and efficacy data and information on the SAFEGUARD and PRISE-hATG studies. Two oral presentations are scheduled for October 10, alongside three electronic posters covering a clinical drug-level assay, repeat dosing in healthy volunteers and binding to T-cell surface proteins. Presentations will be available on the company’s website after the conference and remain accessible.
SAB Biotherapeutics (SABS) will present new SAB-142 clinical data at the 62nd Annual Meeting of the European Association for the Study of Diabetes, held September 28–October 2, 2026 in Milan, Italy.
Presentations will feature Phase 1 data on SAB-142’s mechanism of action, potential for safe redosing, pharmacokinetic/pharmacodynamic profiles, and early signals of C-peptide preservation in type 1 diabetes. Multiple oral talks and corresponding posters will be delivered by SAB BIO’s clinical and scientific leadership.
SAB BIO (Nasdaq: SABS), a clinical-stage biopharma developing fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes and other autoimmune diseases, will participate in two September 2026 investor events: Citi’s Biopharma Back to School Conference and Morgan Stanley’s 24th Annual Global Healthcare Conference in New York.
SAB BIO (Nasdaq: SABS) reported Q2 2026 results and pipeline progress for lead candidate SAB-142 in type 1 diabetes. The registrational Phase 2b SAFEGUARD trial now has over 60 activated sites across the U.S., Australia, New Zealand, U.K. and EU, with Part B enrollment on track for completion in Q4 2026 and topline data expected in 2H 2027.
The Phase 3 PRISE-hATG study received a grant from Breakthrough T1D and will be co‑funded by SAB BIO, evaluating SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis. SAB BIO reported $208.0 million in cash, cash equivalents and investment securities at June 30, 2026, guiding operational runway through 2028. Q2 2026 R&D expenses were $16.2 million and G&A expenses were $7.2 million, with a net loss of $22.5 million. The company began construction of a second Tc‑Bovine farm to expand manufacturing capacity and was added to the Russell 3000 and Russell 2000 indexes.
SAB Biotherapeutics (Nasdaq:SABS) will release its second quarter 2026 financial results on the morning of Thursday, August 6, 2026, and will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.
The Q2 2026 earnings call, titled “SAB BIO’s Q2 2026 Earnings Call”, can be accessed via domestic dial-in at 1-800-343-4136, international dial-in at 1-203-518-9843, using Conference ID SABBIO. A replay of the audio webcast will be available afterward in the Investors & Media section of the company’s website at ir.sab.bio.